The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

As per The Business Research Company’s Non Hodgkin Lymphoma (NHL) Global Market Report 2024, the non-Hodgkin lymphoma (NHL) market is expected to show significant growth in the forecast period.

The non-Hodgkin lymphoma (NHL) market has witnessed strong growth in recent years, driven by factors such as increased incidence of NHL, advancements in diagnostics, chemotherapy, and immunotherapy, and improved survival rates. The market, valued at $9.34 billion in 2023, is projected to reach $10.23 billion in 2024, with a compound annual growth rate (CAGR) of 9.4%. This growth is expected to continue in the forecast period, reaching $14.13 billion by 2028, with a CAGR of 8.4%.

Rising Geriatric Population Driving Market Growth

One of the key drivers of growth in the NHL market is the rising geriatric population. The geriatric population, defined as individuals aged 65 or older, has a higher incidence of NHL, emphasizing the need for specialized care and treatment for elderly individuals facing this hematological malignancy. With the global geriatric population expected to reach 2.1 billion by 2050, the demand for NHL treatments is expected to rise significantly.

View More On The Non Hodgkin Lymphoma (NHL) Market Report 2024 – https://www.thebusinessresearchcompany.com/report/non-hodgkin-lymphoma-nhl-global-market-report

 Advancements in Drug Innovations Revolutionizing Treatment Options

Advancements in drug innovations are a key trend in the NHL market, with companies focusing on innovating new products to sustain their position in the market. For example, Genentech Inc. received FDA approval for Lunsumio, a novel bispecific antibody for treating relapsed or refractory follicular lymphoma. This antibody represents a new class of fixed-duration cancer treatment immunotherapy, offering a readily available and off-the-shelf treatment option for patients.

Acquisitions Expanding Product Portfolios

Acquisitions are also shaping the NHL market, with companies acquiring technologies to broaden their product portfolios. For example, AstraZeneca PLC acquired TeneoTwo Inc., a biotechnology company focusing on oncology drug development. This acquisition will strengthen AstraZeneca’s oncology portfolio, adding a pipeline phase I clinical-stage CD19/CD3 T-cell engager, TNB-486, for the treatment of relapsed and refractory B-cell non-Hodgkin lymphoma.

Market Segmentation and Regional Outlook

The NHL market is segmented by type, treatment, route of administration, distribution channel, and end-users. By region, North America was the largest market in 2023, with Asia-Pacific expected to be the fastest-growing region during the forecast period.

Request A Sample Of The Global Non Hodgkin Lymphoma (NHL) Market Report 2024:
https://www.thebusinessresearchcompany.com/sample_request?id=10676&type=smp